SurePath and Liquid-Based Cytology (LBC): Advancing Cervical Cancer Screening for Women in Malaysia
Cervical cancer remains a significant public health concern for women globally, including in Malaysia, where it is one of the top three most common cancers among women. While cervical cancer is preventable and treatable when detected early, many cases in Malaysia are diagnosed in advanced stages due to inadequate screening. SurePath and other Liquid-Based Cytology (LBC) tests represent a major advancement in cervical screening, offering improved accuracy, sample quality, and early detection of pre-cancerous changes. Promoting access to and awareness of LBC in Malaysia is a critical step in reducing cervical cancer rates and saving lives.
What is Liquid-Based Cytology (LBC)?
LBC is a modern method of cervical screening that enhances the traditional Pap smear technique. While both tests aim to detect abnormal cells in the cervix that could develop into cancer, LBC offers several advantages over conventional Pap smears.
Instead of smearing collected cervical cells directly onto a slide (as in the traditional Pap test), LBC involves rinsing the collection brush into a vial containing a liquid preservative. The sample is then processed in a laboratory to remove excess mucus, blood, and debris, resulting in a cleaner, more accurate slide for evaluation.
What is SurePath?
SurePath is one of the leading brands of liquid-based cytology tests used worldwide. It offers:
- High-quality sample preservation
- Enhanced detection of abnormal or precancerous cells
- The ability to perform HPV testing from the same sample
- Improved slide clarity, reducing unsatisfactory sample rates
SurePath is approved by regulatory authorities such as the FDA and is widely used in many developed healthcare systems. It is now increasingly available in Malaysian private clinics and some government facilities as part of efforts to modernize cervical screening.
Why is LBC/SurePath Important for Women in Malaysia?
- Improved Accuracy and Early Detection
Traditional Pap smears can sometimes miss abnormal cells due to poor sample quality or inadequate slide preparation. LBC techniques like SurePath significantly reduce false negatives and increase the detection of precancerous lesions, allowing for earlier and more effective intervention.
- More Reliable Results
SurePath and other LBC tests result in fewer unsatisfactory samples, which means fewer women are called back for repeat tests. This is especially important in Malaysia, where access to healthcare may be limited in rural areas, and return visits are often inconvenient.
- Supports HPV Testing
High-risk human papillomavirus (HPV) infection is the primary cause of cervical cancer. SurePath allows for co-testing—HPV DNA testing and cytology from the same sample—making it a more comprehensive screening tool. This dual approach is part of international best practices and is being increasingly recommended in Malaysia.
- Better Patient Experience
LBC collection is generally more comfortable, and results are more reliable, reducing the need for repeat sampling. This improves patient trust and compliance, which is essential in public health efforts to boost screening rates.
- Addressing Cervical Cancer Burden in Malaysia
According to the Malaysian Ministry of Health and NGOs such as the National Cancer Society, cervical cancer is largely preventable, yet screening uptake remains low—especially in underserved communities. Introducing SurePath and LBC as standard practices can strengthen the national cervical screening program and support Malaysia’s goal to align with the World Health Organization’s strategy to eliminate cervical cancer.
When Should Women in Malaysia Get Screened?
Current Malaysian guidelines recommend that women:
- Begin cervical cancer screening from age 21 or within three years of becoming sexually active
- Continue regular screening every 3 years with Pap smear, or every 5 years with LBC/HPV co-testing (if available)
- Women over 65 may discontinue screening if they have had consistent normal results
Women should consult their doctors for personalized recommendations, especially if they have risk factors such as:
- Early onset of sexual activity
- Multiple sexual partners
- Smoking
- Weakened immune system
- A history of abnormal Pap smears
Conclusion
SurePath and other liquid-based cytology methods are revolutionizing cervical cancer screening by making it more accurate, efficient, and patient-friendly. For women in Malaysia, the adoption of LBC and HPV co-testing represents a major step forward in the fight against cervical cancer. With better awareness, access, and policy support, these technologies can help reduce preventable deaths and improve women’s health outcomes nationwide. Empowering women to participate in regular screening—using modern methods like SurePath—can ultimately save thousands of lives.